Clinical Trial Search

Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183

Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities

Primary: Percentage of Patients With Favourable Outcome (Modified Rankin Scale (mRS) 0-1) at 1 Year — 27.7; 23.8 Percentage of Participants — p=<0.001

Primary: The Percentage of Patients With Modified Rankin Scale (mRS 0-1) (Favourable Outcome) Response at Day 90 After Stroke Onset by Face-to-face Interview With Patient — 42.5…

Primary: All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients — 2.6; 0.8 Percentage of participants

Primary: National Institutes of Health Stroke Scale Score — 8.78; 7.80; 8.85; 5.48 units on a scale

Primary: Ordinal Modified Rankin Scale (mRS) Score at Day 90 — 35; 31; 38; 30 Count of participants

Primary: Percentage of Patients Who Received Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Within 3 Hours of Symptom Onset Among 2 Hours Intravenous…

Primary: Telephone Modified Rankin Scale (Centralised, Blinded Assessment) — 58; 70; 75; 84 participants — p=0.683

Primary: Number of Participants With Symptomatic Intracerebral Hemorrhage Within 36 Hours of Treatment — 0 participants

Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants

Primary: Safety Outcome: Rate of Symptomatic Intracranial Hemorrhage (SICH) in the Active Treatment Arms Compared to Sham Arm — 0; 1; 0 Participants

Primary: Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1 — 72.7; 70.3 Percentage of participants

Primary: Modified Rankin Score

Primary: Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) — 100; 88 minutes

Primary: Number of Patients With Serious Bleeding Events — 0; 1 Participants

Primary: The Percentage of Change in Optical Cerebral Blood Flow (oCBF) During Bolus Normal Saline Compared to Baseline, as Measured by Diffuse Correlation Spectroscopy (DCS)…

Primary: Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR]) — 2.17; 2.37 mL — p=0.779

Primary: Analysis of the National Institutes of Health Stroke Scale (NIHSS) Total Score Area Under the Curve During the Treatment Period — 3.83; 3.13 units on a scale

Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants

Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF

Primary: Number of Subjects With Symptomatic Intracerebral Hemorrhage — 1; 1 Participants

Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants

Primary: Myelin Basic Protein (MBP) Comparison Between the Two Groups Before and After Treatment — 0.42; 0.64; 0.41; 0.71 pg/ml

Primary: Study Related Serious Adverse Events (SR-SAE) — 0 Events

Primary: Frequency of Symptomatic Hemorrhagic Transformation Safety of iv Rt-PA in Wake up Stroke Patients — 0 cases.

Primary: 90-day Global Disability Assessed Via the Blinded Evaluation of Modified Rankin Score (mRS). — 17; 8; 25; 10 Participants

Primary: Functional Outcome as Defined by a mRS of 0-2 at 90 Days Post-procedure — 57 Participants

Primary: A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. — 681; 683 participants

Primary: Number of Participants With 90-day Favorable Outcome — 106; 93 Participants